Nektar Therapeutics Liabilities, Fair Value Adjustment
Nektar Therapeutics (NKTR) reported Liabilities, Fair Value Adjustment of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-05.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures
us-gaap:LiabilitiesFairValueAdjustment · last filed 2024-03-05
- Nektar Therapeutics liabilities, fair value adjustment for the quarter ending 2023-12-31 was $0.00.
- Nektar Therapeutics liabilities, fair value adjustment for the quarter ending 2023-09-30 was $0.00.
- Nektar Therapeutics liabilities, fair value adjustment for the quarter ending 2023-06-30 was $0.00.
- Nektar Therapeutics liabilities, fair value adjustment for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Nektar Therapeutics liabilities, fair value adjustment for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Nektar Therapeutics liabilities, fair value adjustment for fiscal 2022 was $33.43M.
- Nektar Therapeutics liabilities, fair value adjustment for fiscal 2021 was -$8.02M.
- Nektar Therapeutics liabilities, fair value adjustment for fiscal 2020 was $0.00.
| Period end | Liabilities, Fair Value Adjustment 3 month | Liabilities, Fair Value Adjustment 6 month | Liabilities, Fair Value Adjustment 9 month | Liabilities, Fair Value Adjustment 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $0.00 derived: sum of 2 quarters · filed 2024-03-05 | $0.00 derived: sum of 3 quarters · filed 2024-03-05 | $0.00 10-K · filed 2024-03-05 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | $0.00 derived: sum of 4 quarters · filed 2024-03-05 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | $0.00 derived: sum of 3 quarters · filed 2024-03-05 | $0.00 derived: sum of 4 quarters · filed 2024-03-05 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-10 | $0.00 derived: sum of 2 quarters · filed 2024-03-05 | $0.00 derived: sum of 3 quarters · filed 2024-03-05 | $0.00 derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $0.00 derived: sum of 2 quarters · filed 2024-03-05 | $0.00 derived: sum of 3 quarters · filed 2024-03-05 | $33.43M 10-K · filed 2024-03-05 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $33.43M 10-Q · filed 2023-11-08 | $33.04M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-09 | $33.43M 10-Q · filed 2023-08-09 | $33.04M derived: sum of 3 quarters · filed 2024-03-05 | $29.72M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $33.43M 10-Q · filed 2023-05-10 | $33.04M derived: sum of 2 quarters · filed 2024-03-05 | $29.72M derived: sum of 3 quarters · filed 2024-03-05 | $27.00M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | -$383.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$3.71M derived: sum of 2 quarters · filed 2024-03-05 | -$6.42M derived: sum of 3 quarters · filed 2024-03-05 | -$8.02M 10-K · filed 2024-03-05 |
| 2021-09-30 | -$3.33M 10-Q · filed 2022-11-04 | -$6.04M derived: sum of 2 quarters · filed 2022-11-04 | -$7.64M 10-Q · filed 2022-11-04 | -$7.64M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$2.71M 10-Q · filed 2022-08-05 | -$4.31M 10-Q · filed 2022-08-05 | -$4.31M derived: sum of 3 quarters · filed 2023-02-28 | -$4.31M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$1.60M 10-Q · filed 2022-05-06 | -$1.60M derived: sum of 2 quarters · filed 2023-02-28 | -$1.60M derived: sum of 3 quarters · filed 2023-02-28 | -$1.60M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-05 | $0.00 derived: sum of 2 quarters · filed 2021-11-05 | $0.00 10-Q · filed 2021-11-05 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-06 | $0.00 10-Q · filed 2021-08-06 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-07 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |